Modality profile: Bi-Specifics and cytokines at #ASCO23
- blonca9
- Jun 3, 2023
- 1 min read
Updated: Jun 15, 2023
Xencor CEO Bassil Dahiyat walks us through the idea behind bi-specific antibodies and cytokines in cancer research.
top of page
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.
Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.
bottom of page